Session V: Presentation of Selected Non-Colorectal Cancer Abstracts

Chair(s)

• 

  Florian Lordick, MD, PhD

  Leipzig University Medical Center
  Leipzig, Germany
• 

  Juan Manuel O'Connor, MD, MSc

  Instituto Alexander Fleming
  BUENOS AIRES, Argentina

Presentations:

• 08:00 – 08:08

  SO-4: Individual Participant Data Network Meta-Analysis (IPD-NMA) of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastro-esophageal junction carcinoma
  

  Abstract Presenter: Matthieu Faron
• 08:08 – 08:16

  SO-5: Disease-free survival as surrogate for overall survival in neoadjuvant chemo(radio)therapy treatment of esophageal or gastro-esophageal junction carcinoma: an analysis of 4518 individual patients and 22 trials
  

  Abstract Presenter: Nicolas Cabrit
• 08:16 – 08:24

  SO-6: Novel frailty index predicts short-term outcomes after esophagectomy in elderly patients with esophageal cancer
• 08:24 – 08:34

  Discussant: SO-4, SO-5, SO-6
  

  Discussant: Karin Haustermans, MD, PhD – University Hospital Gasthuisberg
• 08:34 – 08:46

  O-3: Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): expanded efficacy and safety analyses from CheckMate 648
  

  Abstract Presenter: Ian Chau
• 08:46 – 08:58

  O-4: Trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with pretreated metastatic esophagogastric adenocarcinoma (mEGA): A Danish randomized trial (LonGas)
  

  Abstract Presenter: Per Pfeiffer
• 08:58 – 09:06

  SO-7: Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial
  

  Abstract Presenter: Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center
• 09:06 – 09:14

  SO-8: Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR)
  

  Abstract Presenter: Hisato Kawakami
• 09:14 – 09:25

  Discussant: O-3, O-4, SO-7, SO-8
  

  Discussant: Kei Muro, MD and PhD – Aichi Cancer Center Hospital